Actividad in vitro de la tigeciclina en cepas bacterianas cultivadas en muestras clínicas de pacientes atendidos en un hospital universitario

Barra lateral del artículo

Contenido principal del artículo

Jaime Alberto López Vargas
  • Biografía

    Especialista en Microbiología y Parasitología Médicas. Coordinador Laboratorio Microbiología Hospital Pablo Tobón Uribe. Medellín, Colombia.

Resumen

Introducción: el constante incremento de la resistencia bacteriana a los antibióticos, hace necesario disponer de herramientas terapéuticas. La tigeciclina es un nuevo antibiótico, derivado de la minociclina, y ha demostrado excelente actividad in vitro en contra de un amplio espectro de microorganismos.


Objetivo: describir la sensibilidad de las bacterias aerobias grampositivas y gramnegativas a la tigeciclina, aisladas de muestras clínicas, en un hospital de cuarto nivel de atención.


Metodología: se realizó la identificación por medios convencionales y el estudio de sensibilidad a la tigeciclina por el método de difusión con disco, a bacterias cultivadas de muestras (con excepción de orina) provenientes de pacientes atendidos en el servicio de Urgencias y ambulatorios.


Resultados: en total se estudiaron 2 515 bacterias. El 100% de las cepas de Staphylococcus aureus (651), Staphylococcus coagulasa negativa (382) y Enterococcus spp. (276) es sensible a la tigeciclina. Del mayor número de enterobacterias analizadas, Escherichia coli (511) presentó una sensibilidad del 99.8%, Klebsiella pneumoniae (332) un 93.1% y Enterobacter cloacae (129) del 96.9%. Las cepas que presentaron mecanismos de resistencia como Staphylococcus spp. oxacilino resistentes y enterobacterias productores de betalactamasas de espectro extendido presentaron altos porcentajes de sensibilidad a la tigeciclina.


Conclusiones: la tigeciclina, como en la mayoría de los estudios realizados en otras regiones del mundo, presentó una excelente actividad in vitro en las bacterias cultivadas en las muestras clínicas de este Hospital y, por tanto, podría ser una opción en el tratamiento, tanto empírico como terapéutico, de las infecciones en las que esté indicado su uso.

Palabras clave:
Tigecycline, Gram-Positive Cocci, Enterobacteriaceae Tigeciclina, cocos grampositivo, enterobacterias

Detalles del artículo

Referencias

Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, et al. The epidemic of antibioticresistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis. 2008; 46(2):155-64.

Pankey GA. Tigecycline. J Antimicrob Chemother. 2005; 56(3):470-80.

Biedenbach DJ, Beach ML, Jones RN. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases. Diagn Microbiol Infect Dis. 2001; 40(4):173-7.

Patel R, Rouse MS, Piper KE, Steckelberg JM. In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis. 2000; 38(3):177-9.

Fritsche TR, Kirby JT, Jones RN. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections. Diagn Microbiol Infect Dis. 2004; 49(3):201-9.

Gales AC, Jones RN. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn Microbiol Infect. Dis 2000; 36(1):19-36.

Betriu C, Rodríguez-Avial I, Gómez M, Culebras E, López F, Alvarez J, et al.; Spanish Tigecycline Group. Timicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second multicenter study. Diagn Microbiol Infect Dis. 2006; 56(4):437-44.

Milatovic D, Schmitz FJ, Verhoef J, Fluit AC. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents Chemother. 2003; 47(1):400-4.

Zhang YY, Zhou L, Zhu DM, Wu PC, Hu FP, Wu WH, et al. In vitro activities of tigecycline against clinical isolates from Shanghai, China. Diagn Microbiol Infect Dis. 2004; 50(4):267-81.

Waites KB, Duffy LB, Dowzicky MJ. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob Agents Chemother. 2006; 50(10):3479- 84.

Isenberg HD, Washington JA, Ballows A, Sonnenwirth AC. Collection, handling, and processing of specimens. In: Lennette EH, Ballows A, Hausler WJ Jr, Shadomy HJ, editors. Manual of clinical microbiology. Washington, DC: American Society for Microbiology; 1985. p. 73- 98.

Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Disk Susceptibility Tests: approved Standard. 9. ed. Wayne: CLSI; 2006. M2- A9.

Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: informational Supplement. 16. ed. Wayne: CLSI; 2006. M100-S16.

Hope R, Warner M, Potz NA, Fagan EJ, James D, Livermore DM. Activity of tigecycline against ESBL-producing and AmpC-hyperproducing Enterobacteriaceae from south-east England. J Antimicrob Chemother. 2006; 58(6):1312-4.

Samra Z, Ofir O, Lishtzinsky Y, Madar-Shapiro L, Bishara J. Outbreak of carbapenem-resistant Klebsiella pneumoniae producing KPC-3 in a tertiary medical centre in Israel. Int J Antimicrob Agents. 2007; 30(6):525-9.

Naesens R, Ursi JP, Van Schaeren J, Jeurissen A. In vitro activity of tigecycline against multidrug-resistant Enterobacteriaceae isolates from a Belgian hospital. Eur J Clin Microbiol Infect Dis. 2009; 28(4):381-4.

Halstead DC, Abid J, Dowzicky MJ. Antimicrobial susceptibility among Acinetobacter calcoaceticusbaumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance Trial. J Infect. 2007; 55(1):49-57.

Reinert RR, Low DE, Rossi F, Zhang X, Wattal C, Dowzicky MJ. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother. 2007; 60(5):1018-29.

Kresken M, Leitner E, Brauers J, Geiss HK, Halle E, von Eiff C, et al.; German Tigecycline Evaluation Surveillance Trial Study Group. Susceptibility of common aerobic pathogens to tigecycline: results of a surveillance study in Germany. Eur J Clin Microbiol Infect Dis. 2009; 28(1):83-90.

Bouchillon SK, Iredell JR, Barkham T, Lee K, Dowzicky MJ. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the AsiaPacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST). Int J Antimicrob Agents. 2009; 33(2):130-6.

Rossi F, García P, Ronzon B, Curcio D, Dowzicky MJ. Rates of antimicrobial resistance in Latin America (2004-2007) and in vitro activity of the glycylcycline tigecycline and of other antibiotics. Braz J Infect Dis. 2008; 12(5):405-15.

Nørskov-Lauritsen N, Marchandin H, Dowzicky MJ. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007). Int J Antimicrob Agents. 2009 Mar 31 [Epub ahead of print].

Martínez E, Alquichire C, Pérez C, Prada G, Rozo V, Larotta J. Comparación de la actividad in vitro de la tigeciclina contra microorganismos causantes de infección en pacientes hospitalizados en Colombia: estudio de evaluación y vigilancia de tigeciclina,TEST. Infectio. 2007; 11(4):159-70.

Fernández Canigia L, Kaufman S, Lanata L, Vay C, Giovanakis M, Bantar C; Argentinean Tigecycline Surveillance Group. Multicenter study to assess the in vitro activity of tigecycline by disk diffusion test against clinical isolates from Argentina. Chemotherapy. 2009; 55(1):20-7.

Henwood CJ, Gatward T, Warner M, James D, Stockdale MW, Spence RP, et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother. 2002; 49(3):479-87.

Jones RN, Ferraro MJ, Reller LB, Schreckenberger PC, Swenson JM, Sander HS. Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J Clin Microbiol. 2007; 45(1):227– 30.

Thamlikitkul V, Tiengrim S. Effect of different MuellerHinton agars on tigecycline disc diffusion susceptibility for Acinetobacter spp. J Antimicrob Chemother. 2008; 62(4):847-8.